Inhibition of interleukin 1 (IL-1)-elicited leukocytosis and LPS-induced fever by soluble immune response suppresor (SIRS)

Michal Zimecki*, H. William Schnaper, Zbigniew Wieczorek, David R. Webb, Carl W. Pierce

*Corresponding author for this work

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

IL-1-induced leukocytosis was inhibited or blocked in a dose-dependent manner by SIRS, an antigen-nonspecific suppressive lymphokine, when administered intravenously or per os to CBA mice. Timing experiments showed that SIRS effectively inhibited the leukocytosis when administered within 30 minutes of the IL-1. An antipyrogenic activity of SIRS was observed in rabbits injected intravenously with LPS. SIRS, given intravenously in one or two doses, markedly reduced LPS-induced fever. SIRS (2000 units) was a more effective antipyretic agent than aspirin (3 mg/kg body weight, intramuscularly). The results suggest that SIRS may be a potential drug for use in IL-1-mediated disorders.

Original languageEnglish (US)
Pages (from-to)39-46
Number of pages8
JournalImmunopharmacology
Volume19
Issue number1
DOIs
StatePublished - Jan 1 1990

Keywords

  • Activity of IL-1 in vivo
  • SIRS

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Inhibition of interleukin 1 (IL-1)-elicited leukocytosis and LPS-induced fever by soluble immune response suppresor (SIRS)'. Together they form a unique fingerprint.

  • Cite this